Cargando…

Syngeneic leukemia models using lentiviral transgenics

Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Keinan, Nurit, Scharff, Ye’ela, Goldstein, Oron, Chamo, Michael, Ilic, Stefan, Gazit, Roi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893004/
https://www.ncbi.nlm.nih.gov/pubmed/33602907
http://dx.doi.org/10.1038/s41419-021-03477-2
_version_ 1783652972779012096
author Keinan, Nurit
Scharff, Ye’ela
Goldstein, Oron
Chamo, Michael
Ilic, Stefan
Gazit, Roi
author_facet Keinan, Nurit
Scharff, Ye’ela
Goldstein, Oron
Chamo, Michael
Ilic, Stefan
Gazit, Roi
author_sort Keinan, Nurit
collection PubMed
description Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved abilities for overexpression of multiple driving oncogenes simultaneously in normal primary cells, which can be transplanted and followed in vivo. Our experiments demonstrated the induction of primary malignant growth. Leukemia lines that model various types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL), were passaged robustly in congenic wild-type immunocompetent mice. These novel leukemia lines, which may complement previous models, offer the flexibility to generate tailored models of defined oncogenes of interest. The characterization of our leukemia models in immunocompetent animals can uncover the mechanisms of malignancy progression and offer a unique opportunity to stringently test anti-cancer chemotherapies.
format Online
Article
Text
id pubmed-7893004
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78930042021-03-03 Syngeneic leukemia models using lentiviral transgenics Keinan, Nurit Scharff, Ye’ela Goldstein, Oron Chamo, Michael Ilic, Stefan Gazit, Roi Cell Death Dis Article Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved abilities for overexpression of multiple driving oncogenes simultaneously in normal primary cells, which can be transplanted and followed in vivo. Our experiments demonstrated the induction of primary malignant growth. Leukemia lines that model various types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL), were passaged robustly in congenic wild-type immunocompetent mice. These novel leukemia lines, which may complement previous models, offer the flexibility to generate tailored models of defined oncogenes of interest. The characterization of our leukemia models in immunocompetent animals can uncover the mechanisms of malignancy progression and offer a unique opportunity to stringently test anti-cancer chemotherapies. Nature Publishing Group UK 2021-02-18 /pmc/articles/PMC7893004/ /pubmed/33602907 http://dx.doi.org/10.1038/s41419-021-03477-2 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Keinan, Nurit
Scharff, Ye’ela
Goldstein, Oron
Chamo, Michael
Ilic, Stefan
Gazit, Roi
Syngeneic leukemia models using lentiviral transgenics
title Syngeneic leukemia models using lentiviral transgenics
title_full Syngeneic leukemia models using lentiviral transgenics
title_fullStr Syngeneic leukemia models using lentiviral transgenics
title_full_unstemmed Syngeneic leukemia models using lentiviral transgenics
title_short Syngeneic leukemia models using lentiviral transgenics
title_sort syngeneic leukemia models using lentiviral transgenics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893004/
https://www.ncbi.nlm.nih.gov/pubmed/33602907
http://dx.doi.org/10.1038/s41419-021-03477-2
work_keys_str_mv AT keinannurit syngeneicleukemiamodelsusinglentiviraltransgenics
AT scharffyeela syngeneicleukemiamodelsusinglentiviraltransgenics
AT goldsteinoron syngeneicleukemiamodelsusinglentiviraltransgenics
AT chamomichael syngeneicleukemiamodelsusinglentiviraltransgenics
AT ilicstefan syngeneicleukemiamodelsusinglentiviraltransgenics
AT gazitroi syngeneicleukemiamodelsusinglentiviraltransgenics